Parkinson's Blog

Despite being a mainstay of Parkinson’s disease treatment, levodopa, a dopamine-replenishing medication, can cause nasty side-effects with long-term use. A recent human trial found that a new drug significantly reduces these effects, representing a breakthrough milestone in Parkinson’s treatment.

The Parkinson’s support group gathered to offer a platform for members to share, support, and connect with one another.

A recent study reveals an immune mechanism that could explain why Parkinson’s disease affects more men than women. This…

Solving a decades-long mystery.

MeiraGTx and Hologen form a neuro-AI drug development joint venture, with up to $430M in funding to advance Parkinson’s and CNS treatments.

Cure Parkinson’s is supporting the Movers & Shakers new petition, alongside Parkinson’s UK and Spotlight YOPD, to call on the government to take

Harvey Silikovitz shared how a missed voicemail from a “Jeopardy!” producer in 2019 would delay his appearance on the show by more than five years.

A new study links rare ITSN1 mutations to a tenfold increase in Parkinson’s risk, paving the way for targeted treatments.

Parkinson’s disease cases are projected to double globally by 2050, reaching 25 million individuals, according to a recent modeling study published in BMJ. Population aging (increasing median age) emerged as a primary driver of this increase, followed by population growth (rising total number of people), with the largest increases expected in East Asia and among people aged 80 and older.

A new study published in Cell Reports reveals a breakthrough discovery linking genetic variants in the gene ITSN1 to a significantly elevated risk of Parkinson’s disease, a neurodegenerative condition that affects nearly 2% of adults older than 65 years.